Cetuximab NO1 Injection 100?mg/50?mL (Datalai) by Kelun Botai | EGFR?Targeted Biologic | Price comparison

描述

Cetuximab NO1 Injection Description

Product name: Cetuximab N01 injection (Datelai/Kelun Botai)
Packaging specification: 100mg (50ml) ? Product dosage form: injection ? Packaging unit: bottle/box
Approval number: National Medicine Standard S20250006 ? Drug code: 86982635000030
Manufacturer: Sichuan Kelun Botai Biopharmaceutical Co., Ltd.

Cetuximab is a chimeric mouse–human IgG1 monoclonal antibody that competitively binds to the extracellular domain of the Epidermal Growth Factor Receptor (EGFR/HER1), blocking activation by EGF and TGF?? and inhibiting downstream proliferation and survival signaling (MAPK, PI3K/Akt, Jak/Stat)?it.wikipedia.org+8synapse.patsnap.com+8iiab.me+8. It also promotes receptor internalization, antitumor apoptosis, inhibits angiogenesis, and elicits antibody-dependent cellular cytotoxicity (ADCC)?

In China, Kelun Botai’s Cetuximab NO1 is approved for research use only (NMPA S20250006). It’s included in clinical phase III trials for:

• RAS wild?type colorectal cancer (first-line)

• Head and neck squamous cell carcinoma (with radiotherapy)

• KRAS G12C-positive NSCLC?

Cetuximab NO1 Injection Product Specifications

Cetuximab NO1 Injection Mechanism & Research Applications

• EGFR blockade: Prevents ligand-induced activation and downstream signaling (MAPK, PI3K/Akt)

• Receptor internalization: Leads to EGFR downregulation on tumor cells?creativebiolabs.net+6pmc.ncbi.nlm.nih.gov+6synapse.patsnap.com+6.

• ADCC: Recruits immune effectors to kill EGFR-expressing cancer cells?pmc.ncbi.nlm.nih.gov+1synapse.patsnap.com+1.

• Combination synergy: Enhances chemo- or radio-therapy efficacy and overcomes resistance in KRAS wild-type models?.

Use cases in research:

• KRAS wild-type colorectal cancer models

• Head and neck carcinoma + radiotherapy studies

• EGFR pathway signaling / resistance modeling

• Testing in KRAS G12C and NSCLC models

 Why Choose Cetuximab NO1 (Datalai)?

• A locally produced biosimilar to Erbitux® with full regulatory traceability

• Ideal for EGFR-pathway cancer research, ADCC assays, and combination therapy testing

• Included in Phase III clinical pipelines for colorectal and lung cancer

• Pre-filled injection format for reliable dosing in lab protocols

 Related Research Agents

• Panitumumab (EGFR antibody)

• EGFR TKIs: Gefitinib, Erlotinib, Osimertinib

• Radiolabeled EGFR tracers

• Antibody–drug conjugates targeting EGFR

 Summary

Cetuximab NO1 Injection (100?mg/50?mL) by Kelun Botai is a biosimilar EGFR antibody, approved for research in EGFR-driven cancers. It blocks receptor activation, mediates ADCC, and is crucial for preclinical oncology studies.
?? For laboratory research use only — not for human consumption or therapy.